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Background/introduction
The purpose of this retrospective study is to examine the
incidence and imaging appearance of pelvic malignancies
in a symptomatic patient population being screened for
MRgFUS treatment.
Methods
373 women with symptomatic uterine fibroids were
screened with MRI exams with and without contrast uti-
lizing T2 coronal and axial, T2 fat suppressed sagittal, T1
axial precontrast images, and post contrast fat saturated
images in 3 planes. Uterine masses were classified by their
intensity on T2 weighted images relative to normal myo-
metrium (hypointense, isointense, or hyperintense as well
as tissue homogeneity or heterogeneity). The enhance-
ment pattern was also categorized as homogenous or
inhomogeneous. Any extra-uterine masses were also
noted as well as any other incidental pelvic findings.
Results and conclusions
Results: Of the 373 patients (ages 26-61) that underwent
pelvic screening for MRgFUS treatment, 19 presented
with findings suspicious for cancer and after further eva-
luation, 7 of these patients (1.9 %) were confirmed to
have a pelvic malignancy. 5 patients had a uterine sar-
coma, 1 had endometrial carcinoma and 1 had ovarian
carcinoma. Three out of the five sarcomas appeared
markedly heterogeneous on T2 weighted images with ill-
defined dark areas and bright fluid components and
demonstrated heterogeneous, poorly defined areas of
enhancement throughout. The remaining 2 sarcomas
appeared more fluid in nature with eccentric, enhancing
soft tissue components and multiple septations.
The endometrial carcinoma appeared as an intra-cavi-
tary mass with ill-defined margins with a blood clot in
the endometrium. This finding is highly unusual, as a
large endometrial clot is not typically seen in cases
where irregular bleeding was noted for fibroids. The
ovarian carcinoma appeared as an extra-uterine mass
with metastatic spread to the pelvic lymph nodes. Malig-
nancy was considered in the remaining 12 patients due
to the MRI imaging characteristics listed in Table 1
below. Three of these patients were excluded from
MRgFUS treatment, but in retrospect had non-suspicious
findings. Contact information was not available to obtain
a definitive diagnosis for the other 9 patients. Conclu-
sions: 1.9% of patients with suspected fibroid disease
were found to harbor a pelvic malignancy following MRI
screening exams for MRgFUS. These findings suggest
that before any treatment for pelvic pathology, MRI
screening should be used to guide physicians to the
appropriate treatment modality (surgical vs. minimally
invasive procedures). It is equally important to avoid
delayed diagnosis and unintended treatment of malignant
diseases with non-excisional approaches at this time.
MRI pelvis exams may also help direct patients with
more typical benign uterine fibroids to both non-invasive
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Table 1. Patients excluded from MRgFUS treatment due
to the possibility of underlying malignancy
Reason for Suspected Malignancy Number of
Patients











Heterogeneous enhancement with well-defined
hypo-enhancement
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treatments (MRgFUS or uterine artery embolization
(UAE)) or surgery (laparoscopy or open surgical proce-
dures). The more liberal use of MRI pelvis exams to
screen and characterize pelvic pathology in symptomatic
women can help avoid recent deleterious outcomes with
morcellation procedures of unsuspected malignancies.
With increasing familiarity with the MR appearance of
uterine pathology and attentive evaluation of screening
studies, early diagnosis of pelvic malignancy may be
achieved.
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Figure 1 Sagittal T2-fat suppressed image depicting a markedly heterogeneous uterine sarcoma.
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